The Efficacy and Safety of Coenzyme Q10 in Parkinson's Disease: a Meta-analysis of Randomized Controlled Trials

Overview

Journal Neurol Sci

Specialty Neurology

Date 2016 Nov 11

PMID 27830343

Citations 38

Authors

Zhen-Guo Zhu

Miao-Xuan Sun

Wan-Li Zhang

Wen-Wen Wang

Yi-Mei Jin

Cheng-Long Xie

Affiliations

Soon will be listed here.

Abstract

The objective of this meta-analysis was to evaluate the effects of coenzyme Q10 (CoQ10) for the treatment of Parkinson's disease (PD) patients in order to arrive at qualitative and quantitative conclusions about the efficacy of CoQ10. Databases searched included PubMed, Google scholar, CNKI, Wan-Fang, and the Cochrane Library from inception to March 2016. We only included sham-controlled, randomized clinical trials of CoQ10 intervention for motor dysfunction in patients with PD. Relevant measures were extracted independently by two investigators. Weighted mean differences (WMD) were calculated with random-effects models. Eight studies with a total of 899 patients were included. Random-effects analysis revealed a pooled WMD of 1.02, indicating no significant difference when CoQ10 treatment compared with placebo in terms of UPDRS part 3 (p = 0.54). Meanwhile, the effect size of UPDRS part 1, UPDRS part 2, and total UPDRS scores were similar in CoQ10 group with in placebo group (p > 0.05). Moreover, we found CoQ10 was well tolerated compared with placebo group. Subgroup analysis showed that the effect size of CoQ10 in monocentric studies was larger than in multicenter studies. Using the GRADE criteria, we characterized the quality of evidence presented in this meta-analysis as moderate to high level. The current meta-analysis provided evidence that CoQ10 was safe and well tolerated in participants with PD and no superior to placebo in terms of motor symptoms. According to these results, we cannot recommend CoQ10 for the routine treatment of PD right now.

Citing Articles

The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation.

Velickovic U, Selakovic D, Jovicic N, Mitrovic M, Janjic V, Rosic S Biomedicines. 2025; 13(2).

PMID: 40002925 PMC: 11853207. DOI: 10.3390/biomedicines13020512.

Reversing Signs of Parkinsonism in a Cell Model Using Mitochondria-Targeted Organoiridium Catalysis.

Jana R, Nguyen H, Yan G, Chen T, Do L J Med Chem. 2025; 68(2):1970-1983.

PMID: 39749732 PMC: 11757046. DOI: 10.1021/acs.jmedchem.4c02741.

Iron(ing) out parkinsonisms: The interplay of proteinopathy and ferroptosis in Parkinson's disease and tau-related parkinsonisms.

da Costa Caiado M, Dolga A, den Dunnen W Redox Biol. 2024; 79():103478.

PMID: 39721496 PMC: 11732237. DOI: 10.1016/j.redox.2024.103478.

Understanding coenzyme Q.

Wang Y, Lilienfeldt N, Hekimi S Physiol Rev. 2024; 104(4):1533-1610.

PMID: 38722242 PMC: 11495197. DOI: 10.1152/physrev.00040.2023.

Crosstalk between Oxidative Stress and Inflammation Caused by Noise and Air Pollution-Implications for Neurodegenerative Diseases.

Kuntic M, Hahad O, Munzel T, Daiber A Antioxidants (Basel). 2024; 13(3).

PMID: 38539800 PMC: 10967531. DOI: 10.3390/antiox13030266.

References

Storch A, Jost W, Vieregge P, Spiegel J, Greulich W, Durner J . Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007; 64(7):938-44. DOI: 10.1001/archneur.64.7.nct60005. View

Guyatt G, Oxman A, Montori V, Vist G, Kunz R, Brozek J . GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011; 64(12):1277-82. DOI: 10.1016/j.jclinepi.2011.01.011. View

Shults C . Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol Ther. 2005; 107(1):120-30. DOI: 10.1016/j.pharmthera.2005.02.002. View

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

Liu J, Wang L, Zhan S, Xia Y . Coenzyme Q10 for Parkinson's disease. Cochrane Database Syst Rev. 2011; (12):CD008150. DOI: 10.1002/14651858.CD008150.pub2. View

Schapira A, Mann V, Cooper J, Dexter D, Daniel S, Jenner P . Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 1990; 55(6):2142-5. DOI: 10.1111/j.1471-4159.1990.tb05809.x. View

Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J . The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One. 2011; 6(10):e25491. PMC: 3196500. DOI: 10.1371/journal.pone.0025491. View

Dorsey E, Constantinescu R, Thompson J, Biglan K, Holloway R, Kieburtz K . Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2006; 68(5):384-6. DOI: 10.1212/01.wnl.0000247740.47667.03. View

Horvath T, Diano S, Leranth C, Garcia-Segura L, Cowley M, Shanabrough M . Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease. Endocrinology. 2003; 144(7):2757-60. DOI: 10.1210/en.2003-0163. View

10.

Klingelhoefer L, Reichmann H . Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. Nat Rev Neurol. 2015; 11(11):625-36. DOI: 10.1038/nrneurol.2015.197. View

11.

Muller T, Buttner T, Gholipour A, Kuhn W . Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003; 341(3):201-4. DOI: 10.1016/s0304-3940(03)00185-x. View

12.

Seet R, Lim E, Tan J, Quek A, Chow A, Chong W . Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson's disease?. Antioxid Redox Signal. 2014; 21(2):211-7. DOI: 10.1089/ars.2013.5801. View

13.

Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S . Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454):1490. PMC: 428525. DOI: 10.1136/bmj.328.7454.1490. View

14.

Spindler M, Beal M, Henchcliffe C . Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009; 5:597-610. PMC: 2785862. DOI: 10.2147/ndt.s5212. View

15.

Negida A, Menshawy A, El Ashal G, Elfouly Y, Hani Y, Hegazy Y . Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. CNS Neurol Disord Drug Targets. 2015; 15(1):45-53. DOI: 10.2174/1871527314666150821103306. View

16.

Choi H, Park H, Koh S, Choi N, Yu H, Park J . Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. Neurotoxicology. 2011; 33(1):85-90. DOI: 10.1016/j.neuro.2011.12.005. View

17.

Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K . Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease. Parkinsonism Relat Disord. 2015; 21(8):911-6. DOI: 10.1016/j.parkreldis.2015.05.022. View

18.

Shults C, Oakes D, Kieburtz K, Beal M, Haas R, Plumb S . Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002; 59(10):1541-50. DOI: 10.1001/archneur.59.10.1541. View

19.

Beal M, Oakes D, Shoulson I, Henchcliffe C, Galpern W, Haas R . A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014; 71(5):543-52. DOI: 10.1001/jamaneurol.2014.131. View

20.

Akushevich I, Kravchenko J, Ukraintseva S, Arbeev K, Yashin A . Age patterns of incidence of geriatric disease in the U.S. elderly population: Medicare-based analysis. J Am Geriatr Soc. 2012; 60(2):323-7. PMC: 3288526. DOI: 10.1111/j.1532-5415.2011.03786.x. View